FDA grants Priority Review to Pfizer's glasdegib for AML

Pfizer Inc. (NYSE:PFE) said FDA accepted and granted Priority

Read the full 91 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE